New hope for tough testicular cancer: cabazitaxel trial shows promise
NCT ID NCT02115165
First seen Apr 16, 2026 · Last updated May 16, 2026 · Updated 4 times
Summary
This study tested a chemotherapy drug called cabazitaxel in 34 men with advanced testicular cancer that had not improved after at least two prior treatments. The goal was to see if the drug could shrink tumors or slow the disease. Cabazitaxel is a newer type of taxane that may work better and have fewer nerve side effects than older drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SEMINOMATOUS GERM-CELL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy Cancer Campus Grand Paris
Villejuif, Val de Marne, 94805, France
Conditions
Explore the condition pages connected to this study.